Exchange: NASDAQ Sector: Financial Services Industry: Shell Companies
-0.19% $10.30
America/New_York / 28 jul 2023 @ 15:51
FUNDAMENTALS | |
---|---|
MarketCap: | 264.20 mill |
EPS: | 0.0600 |
P/E: | 171.67 |
Earnings Date: | Mar 30, 2023 |
SharesOutstanding: | 25.65 mill |
Avg Daily Volume: | 0.0291 mill |
RATING 2023-07-28 |
---|
A- |
Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Sell | |
Return On Asset: | Buy | |
DE: | Sell | |
P/E: | Strong Buy | |
Price To Book: | Buy |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE 171.67 | sector: PE -18.15 |
PE RATIO: COMPANY / INDUSTRY |
---|
0x |
Company: PE 171.67 | industry: PE -25.74 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 10.12 - 10.52 ( +/- 1.97%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-07-28 | Crandell Keith | Sell | 1 600 000 | Class A Common Stock |
2023-07-28 | Arch Venture Fund Xi, L.p. | Sell | 1 600 000 | Class A Common Stock |
2023-07-28 | Deerfield Management Company, L.p. (series C) | Sell | 1 600 000 | Class A Common Stock |
2021-08-05 | Section 32 Fund 3, Lp | Sell | 701 250 | Class B Common Stock, par value $0.0001 per share |
2021-08-05 | Section 32 Fund 3, Lp | Sell | 30 000 | Class B Common Stock, par value $0.0001 per share |
INSIDER POWER |
---|
-100.00 |
Last 28 transactions |
Buy: 8 850 000 | Sell: 14 075 000 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $10.30 (-0.19% ) |
Volume | 0.0022 mill |
Avg. Vol. | 0.0291 mill |
% of Avg. Vol | 7.74 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
DA32 Life Science Tech Acquisition Corp. does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. The company intends to identify business combination targets in the biotechnology and life science infrastructure sectors. DA32 Life Science Tech Acquisition Corp. was incorporated in 2021 and is based in New York, New York.